---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-043338"
form_type: "8-K"
ticker: "SCLX"
cik: "0001820190"
company_name: "Scilex Holding Co"
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T20:17:53.717181+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Scilex sells 4% royalty on Gloperba/Elyxyb to defer Tranche B amortization to 2026

## Summary
- Sold 4% of aggregate net sales of Gloperba and Elyxyb to Oramed, Murchinson, and 3i; consideration is deferral of First Amortization Payment on Tranche B Notes to Oct 8, 2026.
- Entered Security Agreement granting first-priority liens on royalty collateral; Note Agent's lien subordinated to second priority.
- Licensed exclusive worldwide ex-US rights to Gloperba to RoyaltyVest Ltd on 50/50 net revenue split.
- Amended ZTlido Royalty Agreement to allow asset sale without consent if all Debt Instrument obligations are paid in full.
- Transaction closed Feb 28, 2025; grants Royalty and Exclusive Rights under January 2, 2025 Tranche B Consents.

## SEC filing metadata
- accession: 0001193125-25-043338
- form_type: 8-K
- ticker: SCLX
- cik: 0001820190
- company_name: Scilex Holding Co
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1820190/000119312525043338/0001193125-25-043338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1820190/000119312525043338/d864577d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-043338
- JSON: https://secwatch.observer/filing/0001193125-25-043338.json
- Plain text: https://secwatch.observer/filing/0001193125-25-043338.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.